View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 28, 2020

Neurocrine’s newly approved Parkinson’s drug suffers launch delay due to Covid-19

By Victoria Smith

Neurocrine Biosciences has announced it has received FDA approval for Ongentys (opicapone), an oral drug used as an add-on treatment to the standard-of-care drug, levodopa, in patients with Parkinson’s disease experiencing end-of-dose motor fluctuations. However, the company will not launch the drug until later this year, due to Covid-19 disruption.

GlobalData predicts that if the drug launches later in 2020 it will have a slow uptake in its first year, reaching peak global sales of $303M in 2025.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy